Talazoparib

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 623 publications

Profile of Helen M. Piwnica-Worms.

Profile of Helen M. Piwnica-Worms.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 13, 2026

Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion.

Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 10, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

Journal: International journal of clinical oncology
Published: April 09, 2026

Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer Metastasis.

Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer Metastasis.

Journal: bioRxiv : the preprint server for biology
Published: April 03, 2026

Development of Stearic Acid Nanoemulsion for Therapeutic Delivery of Talazoparib Against Breast Cancer.

Development of Stearic Acid Nanoemulsion for Therapeutic Delivery of Talazoparib Against Breast Cancer.

Journal: Pharmaceutics
Published: February 19, 2026

A Design of Experiments-Based Chiral HPLC Method for the Quantification of Talazoparib and Enantiomeric Purity Determination in Pharmaceutical Formulations.

A Design of Experiments-Based Chiral HPLC Method for the Quantification of Talazoparib and Enantiomeric Purity Determination in Pharmaceutical Formulations.

Journal: Chirality
Published: January 30, 2026

DCMiC: a double-cylinder micro-chamber platform for high-throughput drug screening and modeling of microenvironmental resistance in Ewing sarcoma.

DCMiC: a double-cylinder micro-chamber platform for high-throughput drug screening and modeling of microenvironmental resistance in Ewing sarcoma.

Journal: Lab on a chip
Published: December 09, 2025

Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer.

Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer.

Journal: Pharmacological research
Published: December 01, 2025

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.

Journal: NPJ breast cancer
Published: November 29, 2025

A Population-Specific PARP1 Gene Variation Modulates PARP Trapping.

A Population-Specific PARP1 Gene Variation Modulates PARP Trapping.

Journal: bioRxiv : the preprint server for biology
Published: November 26, 2025

Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].

Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].

Journal: European journal of cancer (Oxford, England : 1990)
Published: November 19, 2025

Combined DNA-PK and PARP Inhibition as a Therapeutic Strategy in BRCA-Mutated Prostate Cancer: An in Vitro Pilot Study.

Combined DNA-PK and PARP Inhibition as a Therapeutic Strategy in BRCA-Mutated Prostate Cancer: An in Vitro Pilot Study.

Journal: Technology in cancer research & treatment
Published: November 14, 2025
Showing 1-12 of 623

Last Updated: 04/28/2026